IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial

December 21, 2023

https://www.globenewswire.com/news-release/2023/12/21/2800002/0/en/IO-Biotech-Announces-First-Patient-Dosed-in-Phase-2-Neoadjuvant-Adjuvant-Solid-Tumor-Basket-Trial.html

NEW YORK, Dec. 21, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq:IOBT), a clinical-stage biopharmaceutical company developing novel, immune modulating therapeutic cancer vaccines based on its T-win® platform, announced today that the first patient has been dosed in its Phase 2 trial (NCT05280314) studying treatment with IO102-IO103 in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in neoadjuvant and adjuvant patients with resectable melanoma or squamous cell carcinoma of the head and neck (SCCHN) before and after surgery with curative intent.

Read more at globenewswire.com

Related news for (IOBT)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.